Date: February 28–29, 2000.
Time: 8 AM to 3 PM.
Agenda: To review and evaluate grant applications.
Place: Holiday Inn, Bethesda, MD 20814.
Contact Person: Dharam S. Dhindsa, DVM, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5126, MSC 7854, Bethesda, MD 20892, (301) 435–1174, dhindsad@csr.nih.gov.

This notice is being published in less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Oncological Sciences Initial Review Group, Radiation Study Section.
Date: February 28–March 1, 2000.
Time: 8:30 AM to 5:00 PM.
Agenda: To review and evaluate grant applications.
Place: University Park Marriott, 480 Wakara Way Street, Salt Lake City, UT 84108.
Contact Person: Paul K. Strudler, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4100, MSC 7804, Bethesda, MD 20892, (301) 435–1716.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Infectious Diseases and Microbiology Initial Review Group Experimental Virology Study Section.
Date: February 28–29, 2000.
Time: 8:30 AM to 5:00 PM.
Agenda: To review and evaluate grant applications.
Place: Holiday Inn Georgetown, 2101 Wisconsin Avenue, NW., Washington, DC 20007.
Contact Person: Garrett V. Keefer, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4190, MSC 7808, Bethesda, MD 20892, (301) 435–1152.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Biophysical and Chemical Sciences Initial Review Group Physical Biochemistry Study Section.
Date: February 28–29, 2000.
Time: 8:30 AM to 4:00 PM.
Agenda: To review and evaluate grant applications.
Place: DoubleTree Hotel, 1750 Rockville Pike, Rockville, MD 20852.
Contact Person: Gopa Rakhit, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4154, MSC 7806, Bethesda, MD 20892, (301) 435–1721, rakhitg@csr.nih.gov

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.
Date: February 28–29, 2000.
Time: 8:30 AM to 5:00 PM.
Agenda: To review and evaluate grant applications.
Place: Ritz-Carlton Hotel, 1250 S. Hayes Street, Arlington, VA 22202.
Contact Person: Ron Manning, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4158, MSC 7806, Bethesda, MD 20892, (301) 435–1723.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.
Date: February 28–29, 2000.
Time: 9 AM to 5 PM.
Agenda: To review and evaluate grant applications.
Place: Embassy Suites, Chevy Chase Pavillon, 4300 Military Rd., Wisconsin at Western Ave., Washington, DC 20015.
Contact Person: Julian L. Azorlosa, PhD., Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3190, MSC 7848, Bethesda, MD 20892, (301) 435–1507.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scentific Review Special Emphasis Panel.
Date: February 28–March 1, 2000.
Time: 5 PM to 5 PM.
Agenda: To review and evaluate grant applications.
Place: Ramada Inn, 1775 Rockville Pike, Rockville, MD 20852.
Contact Person: Houston Baker, PhD., Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5128, MSC 7854, Bethesda, MD 20892, 301–435–1175, bakerh@drg.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel.
Date: February 29, 2000.
Time: 8 AM to 6 PM.
Agenda: To review and evaluate grant applications.
Place: Holiday Inn Georgetown, 2101 Wisconsin Avenue, N.W., Washington, DC 20007.
Contact Person: Bruce Mauer, PhD., Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3190, MSC 7848, Bethesda, MD 20892, (301) 435–1187.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scentific Review Special Emphasis Panel.
Date: February 29, 2000.
Time: 10 AM to 12 PM.
Agenda: To review and evaluate grant applications.
Place: NIH, Rockledge 2, Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: John Bishop, PhD., Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5128, MSC 7844, Bethesda, MD 20892, 301–435–1250, bakerh@drg.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine, 93.306; 93.333, Clinical Research, 93.333, 93.337, 93.393–93.396, 93,837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: February 11, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 00–3996 Filed 2–17–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Uteroglobin in Treatment of IgA Mediated Autoimmune Disorders

AGENCY: National Institutes of Health, Public Health Services, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license worldwide to practice the invention embodied in: U.S. Patent Application Serial No. 60/130,434, filed April 21, 1999 entitled, ''Uteroglobin in Treatment of IgA Mediated Autoimmune Disorders'' to Claragen, Inc., having a place of business in Silver Spring, MD. The patent rights in this invention have been assigned to the United States of America.

DATE: Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before May 18, 2000.

ADDRESS: Requests for a copy of the patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Dennis H. Penn, Pharm.D., Technology Licensing Specialist, Office

of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 496–7056, ext. 211; Facsimile: (301) 402–0220.

SUPPLEMENTARY INFORMATION:

Uteroglobin plays a significant role in human renal disease through its effect on the deposition of IgA. This invention relates to the use of uteroglobin and its role in the diagnosis and treatment of IgA nephropathy.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 90 days from the date of this published Notice, NIH received written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The field of use may be limited to the use of the invention for the development of therapeutic and diagnostic applications relating to IgA nephropathy.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: February 14, 2000.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 00–4009 Filed 2–17–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

National Institute of Environmental Health Sciences, National Toxicology Program: Request for Data and Nomination of Expert Scientists To Participate in the Independent Peer Review Evaluation of the Revised Up-and-Down Procedure for Assessing Acute Oral Toxicity; Evaluation of the Up-and-Down Procedure

The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) and the National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) are currently planning a meeting where an Independent Peer Review Panel (hereafter, Panel) will assess the validation status of the revised Up-and-Down Procedure (UDP). This procedure is an updated version of the Organization for Economic Cooperation and Development (OECD) Test Guideline 425 (OECD Guideline for the Testing of Chemicals, Acute Oral Toxicity: Up-and-Down Procedure. Guideline 425, adopted September 21, 1998, OECD, Paris, France, *http://www.oecd.org/ehs/test*). The revised UDP is proposed as a substitute for the existing OECD Test Guideline 401 (OECD Guideline for the Testing of Chemicals, Acute Oral Toxicity, Guideline 401, adopted February 24, 1987, OECD, Paris, France). OECD has proposed that Guideline 401 should be deleted since three alternative methods are not available (OECD Document ENV/JM(99)19, Test Guidelines Programme, Acute Oral Toxicity Testing: Data Needs and Animal Welfare Considerations, 29th Joint Meeting, June 8–11, 1999, Paris, France). Prior to deletion of Guideline 401, U.S. agencies have requested that ICCVAM conduct an independent peer review of the revised UDP to determine the validity of the method as a replacement for Guideline 401. The Panel will evaluate the extent to which the validation and acceptance criteria (outline in NIH Publication 97–3981, Validation and Regulatory Acceptance of Toxicological Test Methods: A Report of the ad hoc Interagency Coordinating Committee on the Validation of Alternative Methods, *http://ntpserver.niehs.nih.gov/htdocs/ICCVAM/iccvam.html*) have been addressed and will provide conclusions and recommendations regarding the usefulness and limitations of the method as a substitute for the traditional acute oral toxicity test method (OECD Guideline 401, 1987). The UDP has the potential to reduce the number of animals required to classify chemicals for acute oral toxicity as compared to Guideline 401.

Nomination of Experts To Serve on Review Panel and Request for Data

The Center welcomes the nomination of scientists with relevant knowledge and experience who might be considered for the Panel to review information on UDP. For each person suggested, his/her name, address, and a brief summary of relevant experience and qualifications should be provided. Where possible, telephone and fax numbers and/or e-mail address should also be provided. Nominations should be sent by mail, fax, or e-mail to NICEATM within 30 days of this notice's publication date. Correspondence should be directed to Dr. William S. Stokes, Co-Chair, ICCVAM, NTP Interagency Center for the Evaluation of Alternative Toxicological Methods, Environmental Toxicology Program, NIEHS/NTP, 79 T.W. Alexander Drive, MD EC–17, P.O. Box 12233, Research Triangle Park, NC 27709; phone: 919–541–7997; fax: 919–541–0947; e-mail: *iccvam@niehs.nih.gov.*

The Center would also welcome data and information from completed, ongoing, or planned studies using or evaluating the UDP. Information should address applicable aspects of the validation and regulatory acceptance criteria provided in NIH Publication 97–3981, Validation and Regulatory Acceptance of Toxicological Test Methods: A Report of the ad hoc Interagency Coordinating Committee on the Validation of Alternative Methods (*http://ntp-server.niehs.nih.gov/htdocs/ICCVAM/iccvam.html*). Where possible, data and information should adhere to the guidance provided in the document, Evaluation of the Validation Status of Toxicological Methods: General Guidelines for Submissions to ICCVAM (*http://iccvam.niehs.nih.gov/doc1.htm*). Both documents are available by request from NICEATM at the address provided above. Information submitted in response to this request will be incorporated into the background material provided to the Panel. The Panel's peer review meeting is anticipated to take place in early to mid-summer, and meeting information (including date and location) and public availability of the background document will be announced in a future **Federal Register** notice and will be posted on the ICCVAM website (*http://iccvam.niehs.nih.gov*). Information about studies with UDP should be sent to Dr. Stokes (contact information provided above).

Persons requesting additional information regarding the rationale for the OECD proposal to delete the OECD Guideline 401 can contact William T. Meyer, U.S. Environmental Protection Agency, Office of Pesticide Programs, phone: 703–305–7188; fax: 703–308–1805; e-mail: *Meyer.WilliamT@epa.gov.* Mail address: Ariel Rios Bldg., 1200 Pennsylvania Avenue, NW, Mail Code 7506C, Washington, DC 20460; Federal Express address: 1921 Jefferson Davis Highway, Room 1104H, Arlington, VA 22202.

Background Information

ICCVAM, with participation by 14 Federal regulatory and research agencies, was established in 1997 to coordinate cross-agency issues relating